Eton Pharma Initiates Pilot Study for ET-700 in Wilson Disease, Targets $100M+ Peak Sales

summarizeSummary

Eton Pharmaceuticals has begun a pilot clinical study for ET-700, an extended-release zinc acetate formulation for Wilson disease, with results expected in H2 2026 and potential peak sales exceeding $100 million.

check_boxKey Events

• Clinical Study Initiated for ET-700

  Eton Pharmaceuticals has dosed the first patient in a pilot clinical study for ET-700, an extended-release zinc acetate formulation for Wilson disease.

• Significant Market Potential

  The CEO projects ET-700 could achieve over $100 million in peak annual sales in the United States if approved, representing a substantial revenue opportunity.

• Study Design and Timeline

  The double-blinded, placebo-controlled study involves 36 healthy volunteers, comparing ET-700 to Galzin® and a placebo. Topline results are anticipated in the second half of 2026, with a pivotal study planned for early 2027 if results are positive.

• Addressing Patient Needs

  The study aims to explore a simpler, more convenient dosing approach for the lifelong treatment of Wilson disease, potentially improving patient adherence.

auto_awesomeAnalysis

This filing signals a significant step forward in Eton Pharmaceuticals' product pipeline, as it initiates a pilot clinical study for ET-700, a potential new treatment for Wilson disease. The CEO's projection of over $100 million in peak annual sales highlights the material revenue opportunity this candidate represents for the company. While this is an early-stage pilot study, its successful progression could significantly enhance the company's long-term growth prospects and address an unmet need for a more convenient dosing regimen in Wilson disease treatment. Investors should monitor the upcoming topline results in the second half of 2026 for further updates on this program.